A5040104069- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Neutropenia and Cancer Infections
- Chronic Lymphocytic Leukemia Research
- Polyomavirus and related diseases
- Mesenchymal stem cell research
- CAR-T cell therapy research
- Helicobacter pylori-related gastroenterology studies
- Cancer Genomics and Diagnostics
- Renal Transplantation Outcomes and Treatments
- Immunotherapy and Immune Responses
- RNA Interference and Gene Delivery
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cytomegalovirus and herpesvirus research
- Immunodeficiency and Autoimmune Disorders
- T-cell and B-cell Immunology
- Reproductive Biology and Fertility
- Dysphagia Assessment and Management
- Congenital Diaphragmatic Hernia Studies
- Inflammatory mediators and NSAID effects
Beth Israel Deaconess Medical Center
2020-2025
Harvard University
2020-2024
Beth Israel Deaconess Hospital
2022
Medical College of Wisconsin
2021
University of Kansas Medical Center
2017-2019
University Medical Center
2017-2019
University Hospital and Clinics
2017-2019
The University of Kansas Cancer Center
2017-2018
University of Kansas
2018
Westwood College
2018
Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of
Abstract Background It is not clear if all Americans have benefitted equally from the availability of chimeric antigen receptor T‐cell (CART) therapy. We aimed to evaluate demographic differences existed among adult patients who received CART therapy and assess predictors treatment outcomes. Methods Records ≥18 years for non‐Hodgkin’s lymphoma, acute lymphoblastic leukemia, multiple myeloma in 2018 were evaluated National Inpatient Sample. Acute complications inhospital mortality compared...
Purpose: Retrospective studies suggest that it may be safe to extend the maintenance flushing interval of implanted ports from once every month, as recommended by manufacturer, 3 months, but no prospective cohort have been done specifically assessing safety and feasibility this intervention. Methods: This was a phase II study in oncologic patients who retained functional port after completion systemic chemotherapy. Patients enrolled had their flushed months were observed until five scheduled...
Os transtornos mentais e comportamentais se constituem como um problema de saúde pública que cresce a cada ano, sendo considerado o mal do século. Assim presente trabalho tem objetivo descrever perfil das internações por Transtornos Mentais Comportamentais no Brasil período 2019 2024. O em questão consiste estudo retrospectivo, descritivo, caráter quantitativo, acerca ocorridas país, meio Sistema Informações Hospitalares Único Saúde (SIH/SUS), disponibilizados pelo Departamento Informática...
ABSTRACT Background In this study, we compared outcomes of intensified myeloablative conditioning regimens using large registry data from Japan (Japanese Society for Transplantation and Cellular Therapy) the United States (Center International Blood Marrow Transplant Research). Methods Adult patients who underwent their first allogeneic hematopoietic stem cell transplantation (HSCT) acute leukemia in remission between 2010 2018 cyclophosphamide plus total‐body irradiation (CY/TBI),...
Clinical trials are critical to scientifically evaluate promising new therapies in oncology, but patient accrual these studies is persistently low. Patient preference plays an important role enrollment trials. We performed this survey the perceptions of newly diagnosed oncology patients about clinical and reasons why they wish or not participate
Compared with reduced-intensity conditioning (RIC), myeloablative (MAC) is generally associated lower relapse risk after allogeneic hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). However, disease-specific factors in AML/MDS can further inform when MAC RIC may yield differential outcomes. We analyzed HCT outcomes stratified by the Disease Risk Index (DRI) 4387 adults (age 40 to 65 years) identify impact of intensity. In...
Renal dysfunction is a recognized risk factor for mortality after allogeneic hematopoietic cell transplantation (alloHCT), yet our understanding of the effect different levels renal at time on outcomes remains limited. This study explores impact degrees HCT and examines whether utilization incremental based estimated glomerular filtration rate (eGFR) improve predictability comorbidity index (HCT-CI). The population included 2 cohorts: cohort 1, comprising patients age ≥40 years who underwent...
Young adult (YA) survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk for late psychosocial challenges, including the inability to return work post-HCT. Work-related outcomes in this population remain understudied, however. We conducted study assess post-HCT status HCT who underwent as YAs and analyze patient-, disease-, HCT-related factors associated with their 1 year Using Center International Blood Marrow Transplant Research data, we evaluated (full-time, part-time...
Gastric secretion can provide valuable information especially when Helicobacter pylori (Hp) infection results in chronic atrophic gastritis (CAG) and intestinal metaplasia (IM) preceding adenocarcinoma (AdCa).Looking for a potential biomarker of malignant transformation the setting inflammation we studied levels prostaglandin E2 (PGE(2)), as well peptide growth factors [epidermal factor (EGF) transforming α (TGFα)], harbingers injury repair, gastric juice aspirated at endoscopy from patients...
Allogeneic hematopoietic cell transplantation (HCT) is an important treatment for many severe hematologic disorders; however, HCT can be associated with significant complications, including organ toxicity, graft-versus-host disease, and relapse. Another serious, but rare, complication the transmission of nonhematologic diseases from donor to recipient. With older donors, risk abnormality may increased. Here we describe inversion 3 constitutional cytogenetic unrelated a recipient, review...